Aptus Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Aptus Capital Advisors's BMY Position: Q2 2026 in Review
Aptus Capital Advisors reduced its Bristol-Myers Squibb (BMY) stake by 6.1% in Q2 2026, selling an estimated $500K and leaving 134,318 shares worth $7.74M. The position accounts for 0.05% of the portfolio, ranked #275.
Aptus Capital Advisors first reported a position in BMY in Q3 2019 and has held it in 22 quarters since. The position peaked at $19M in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Aptus Capital Advisors held 134,318 shares of Bristol-Myers Squibb worth $7.74M as of Q2 2026.
- Aptus Capital Advisors sold 8,713 Bristol-Myers Squibb shares in Q2 2026, an estimated $500K.
- Bristol-Myers Squibb made up 0.05% of Aptus Capital Advisors's portfolio in Q2 2026, its #275 holding.
- Aptus Capital Advisors first reported a position in Bristol-Myers Squibb in Q3 2019 and has held it in 22 quarters since.
- Aptus Capital Advisors's Bristol-Myers Squibb position peaked at $19M in Q1 2025.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.